The ability of the Src family kinases Fyn and Lck to participate in signaling through the T cell receptor is critically dependent on their dual fatty acylation with myristate and palmitate. Here we identify a palmitate analog, 2-bromopalmitate, that effectively blocks Fyn fatty acylation in general and palmitoylation in particular. Treatment of COS-1 cells with 2-bromopalmitate blocked myristoylation and palmitoylation of Fyn and inhibited membrane binding and localization of Fyn to detergent-resistant membranes (DRMs). In Jurkat T cells, 2-bromopalmitate blocked localization of the endogenous palmitoylated proteins Fyn, Lck, and LAT to DRMs. This resulted in impaired signaling through the T cell receptor as evidenced by reductions in tyrosine phosphorylation, calcium release, and activation of mitogen-activated protein kinase. We also examined the ability of long chain polyunsaturated fatty acids (PUFAs) to inhibit protein fatty acylation. PUFAs have been reported to inhibit T cell signaling by excluding Src family kinases from DRMs. Here we show that the PUFAs arachidonic acid and eicosapentaenoic acid inhibit Fyn palmitoylation and consequently block Fyn localization to DRMs. We propose that inhibition of protein palmitoylation represents a novel mechanism by which PUFAs exert their immunosuppressive effects.
Many viral and cellular proteins are modified by fatty acid acylation with myristate or palmitate (1, 2) . For example, all members of the Src family of tyrosine protein kinases are covalently modified by the 14 carbon fatty acid myristate. Myristate is co-translationally attached to a glycine at position 2 of the protein through an amide linkage in a process catalyzed by N-myristoyl transferase (3) (4) (5) . Myristoylation has been shown to be necessary (6, 7) but not sufficient (8) for membrane binding. In addition, all Src proteins use a second membrane targeting signal. For seven of the nine Src family members, this second signal involves modification with the 16 carbon fatty acid palmitate. Palmitate is post-translationally attached to a cysteine residue within an N-terminal Myr-Gly-Cys consensus motif (9) .
Attachment of myristate and palmitate to Src family kinases enhances the localization of these proteins to the plasma membrane, where they must be present to function properly. In addition, protein palmitoylation has been shown to be critical for localization of proteins to specialized subdomains of the plasma membrane that are resistant to detergent extraction (10 -15) . These detergent-resistant microdomains (DRMs), 1 also known as rafts, are enriched in cholesterol, glycosphingolipids, and glycosyl phosphatidylinositol-anchored proteins (16 -18) . Localization to DRMs influences the ability of key signaling molecules to interact with each other and to participate in signaling from the cell surface to the interior of the cell (11, 19 -21) .
The importance of protein fatty acylation is best illustrated in T cell receptor (TCR)-mediated signal transduction. The Src-related kinases Fyn and Lck are highly expressed in cells of hematopoietic origin, particularly lymphocytes (22) , and are required for signaling through the TCR. Protein tyrosine phosphorylation is one of the first events that occurs after binding of antigens to surface receptors in T lymphocytes. Upon receptor engagement, Fyn and Lck phosphorylate tyrosine residues found within multiple immunoreceptor tyrosine-based activation motifs located on the cytosolic portions of the TCR and CD3 chains. Immunoreceptor tyrosine-based activation motif phosphorylation recruits key molecules that mediate downstream signaling, including the tyrosine kinase ZAP-70 (19) . One of the targets for activated ZAP-70 is LAT, a palmitoylated transmembrane protein (10) . Several recent studies have established that the ability of Lck, Fyn, and LAT to function in TCR-mediated signaling depends on their fatty acylation and localization to DRMs. Palmitoylation of Lck was shown to be essential for its signaling function in T lymphocytes (11) . Fyn must be palmitoylated and localized to DRMs to interact with the chain of the TCR (23). Moreover, LAT must be palmitoylated and in DRMs to become tyrosine phosphorylated and participate in downstream signaling (20) .
To date, studies of the role of protein palmitoylation in various cellular pathways have suffered from two major drawbacks. First, in contrast to N-myristoylation, very little is known about the enzymology and biochemistry of protein palmitoylation. Two thioesterases, PPT1 and APT1, have been identified that deacylate palmitoylated Ras and G␣ proteins in vitro (24, 25) . However, the enzyme(s) that catalyze(s) attachment of palmitate to proteins have not been definitively identified. Several recent studies have described purification of palmitoyl acyl transferase (PAT) activities (26 -28) , whereas other reports have documented that nonenzymatic palmitoyla-tion can occur under certain conditions in vitro (29, 30) . Second, nearly all studies reported to date on the role of palmitoylation in cellular functions have been limited to expressing nonacylated mutant forms of proteins in various systems (11, 20) . Although this approach does provide useful information, it is limited by the need to overexpress the mutant proteins. Furthermore, the loss of a cysteine residue, and not the loss of palmitate per se, may impair the ability of the protein to function properly. For example, Hepler et al. showed that cysteine residues at the N terminus of the G q ␣ subunit are important for its interaction with effector and receptor molecules, regardless of their state of palmitoylation (31) .
To overcome the above limitations and to gain further insight into the enzymology of protein palmitoylation and the role it plays in Src family mediated signal transduction in T cells, we searched for specific inhibitors of Fyn and Lck fatty acylation. This search has led to the discovery of 2-bromopalmitate as an inhibitor of Fyn/Lck fatty acylation in general and palmitoylation in particular. Here we show that 2-bromopalmitate preferentially blocks palmitoylation of N-terminally palmitoylated proteins and inhibits membrane binding and localization of Fyn to DRMs in COS-1 cells. Moreover, treatment of Jurkat T cells with 2-bromopalmitate partially blocks localization of endogenous Fyn, Lck, and LAT to rafts and inhibits TCR-mediated signaling events including enhanced tyrosine phosphorylation, calcium flux and activation of MAPK. The identification of 2-bromopalmitate as an inhibitor of fatty acylation of Src family kinases serves to provide insight into the role of protein palmitoylation in Src-mediated signal transduction pathways.
We also examined the ability of long chain fatty acids to inhibit protein fatty acylation. Polyunsaturated fatty acids (PUFAs), particularly the n-3 series, are used clinically as immunosuppressive agents (32) and in the treatment of various inflammatory diseases (33) (34) (35) (36) . Recently, it was reported that PUFAs inhibit T cell signal transduction by displacing Fyn and Lck from the DRMs (37) . The inhibitory effects of PUFAs were hypothesized to be mediated by modification of DRM structure and composition. Here we show that PUFAs act as inhibitors of Fyn palmitoylation and propose a novel mechanism of action by which these agents exert their immunosuppressive effects.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfections-COS-1 cells were maintained and transfected as described previously (9) . Transfection with FUGENE TM 6 Transfection Reagent (Roche Molecular Biochemicals) was carried out according to the manufacturer's instructions. Jurkat T cells were maintained in RPMI 1640 supplemented with 10% FBS, 100 g/ml penicillin and streptomycin, and 100 g/ml sodium pyruvate and glutamine. Cells were transfected by electroporation as described previously (38) .
Antibodies-Monoclonal anti-Fyn, anti-Lck, and anti-Caveolin antibodies used for Western blotting were purchased from Transduction Laboratories (Lexington, KY). The rabbit polyclonal antiserum to Fyn used for immunoprecipitation was described previously (13) . Monoclonal anti-PLC␥-1 and rabbit polyclonals anti-LAT, anti-PI3 kinase, anti-Vav, and anti-ZAP-70 were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Monoclonals anti-Ha-Ras, anti-pERK, antipTyr (PY99), and agarose-conjugated PY99 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-MAPK antibody was purchased from New England Biolabs (Beverly, MA). Fluorescein isothiocyanate-conjugated goat anti-mouse secondary antibody was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). Anti-GFP antibody was purchased from CLONTECH (Palo Alto, CA). OKT3 mAB was obtained from the Monoclonal Antibody Core Facility at Memorial Sloan-Kettering Cancer Center (New York, NY).
Fyn Chimeras-The Fyn Chimeras G␣ o (10)Fyn and GAP43(10)-Fyn have been described previously (12). G2A,C3S Fyn-Ha-Ras was constructed as follows. An antisense oligonucleotide primer was designed that encoded the C-terminal 6 amino acids of Fyn fused in frame to the C-terminal 12 amino acids of Ha-Ras, followed by a stop codon, a SalI site, and a G/C clamp. A sense primer that began 57 bases upstream of a unique BglII site in Fyn was constructed. These two primers were used in a polymerase chain reaction to amplify a fragment containing the C-terminal region of Fyn fused to the Ha-Ras tail. The polymerase chain reaction product was cut with BglII and SalI and used to replace the corresponding region of Fyn in G2AFyn/pSP65. The subcloned construct G2A Fyn Ha-Ras/pSP65 was then digested with NcoI and BglII to remove the 5Ј coding region of Fyn and was ligated to a 1.7-kilobase NcoI/BglII fragment from another Fyn clone containing the G2A,C3S mutation. G2A,C3S Fyn-Ha-Ras/pSP65 was digested with EcoRI and SalI and subcloned into EcoRI-and SalI-cut pCMV5 for COS-1 transfections. The construct was verified by DNA sequencing prior to use in transfections.
Cell Labeling-The syntheses of 13-[ 125 I]iodotridecanoic acid (IC13) or 16-[ 125 I]iodohexanoic acid (IC16) were carried out as described previously (39) . Cell labeling was carried out as described (12, 13) with modifications. Briefly, each 60-mm plate of Fyn transfected COS-1 cells was incubated overnight in DMEM containing 2.5% FBS, 0.25% defatted BSA (Sigma) with or without 100 M 2-bromopalmitate or 50 M PUFA. Prior to labeling, the cells were starved for 1 h with 1 ml of DMEM containing 2% dialyzed FBS and then labeled for 4 h with 25-50 Ci of IC13 or IC16 in DMEM containing 2% dialyzed FBS and 0.5% defatted BSA with or without 2-bromopalmitate or PUFA. Labeled cells were washed three times with cold STE (100 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EDTA) and lysed in 0.6 ml of cold RIPA buffer containing protease inhibitors (10 g/ml each of benzamidine, 4-(2-aminoethyl)-benzene sulfonylfluoride, N ␣ -tosyl-Phe-chloromethylketone, and N ␣ -tosyl-Lys-chloromethylketone, 1.5 g/ml each of leupeptin, pepstatin A, and aprotinin). Lysates were clarified at 100,000 ϫ g for 15 min at 4°C in a Beckman TL-100 ultracentrifuge. Lysates were immunoprecipitated with a rabbit anti-Fyn polyclonal antibody and protein A-agarose.
Immunoprecipitates were washed three times with cold RIPA buffer and suspended in 1ϫ sample buffer containing 100 mM dithiothreitol and subjected to SDS-PAGE. Gels were dried between cellophane and analyzed by phosphorimaging after 12-36 h of exposure. Experiments in Jurkat T cells were carried out as described above, using 2 ϫ 10 7 cells/experiment and reducing the incubation time with 2-bromopalmitate to 3-4 h.
Subcellular Cell Fractionation-Each 60-mm plate of Fyn transfected COS-1 cells was starved for 1 h in DMEM containing 2.5% FBS and 0.5% defatted BSA with or without 100 M 2-bromopalmitate. After overnight culture at 37°C, the cells were fractionated into P100 and S100 fractions, immunoprecipitated with anti-Fyn antibody, subjected to SDS-PAGE, and immunoblotted with anti-Fyn antibody as described previously (9, 12, 13) .
Analysis of the G␣ o (10)Fyn, GAP43(10)Fyn, and G2A,C3S Fyn-HaRas chimera was performed as described above. Analysis of the G12V Ha-Ras and Fyn (16)eGFP constructs was performed as described above, except that the samples were subjected to immunoblotting directly with anti-Ha-Ras antibody or anti-GFP antibody, respectively.
For analysis of newly synthesized Fyn, cells were cultured overnight as described above and then starved for 1 h in DMEM minus methionine and cysteine containing 2% dialyzed FBS and 0.25% defatted BSA with or without 100 M 2-bromopalmitate. Cells were labeled for 5 min with Trans 35 S-Label (ICN, Irvine, CA) and then fractionated as described above. Gels were treated for 20 min with 1 M salicylic acid prior to drying.
Immunofluorescence Microscopy-COS-7 cells were transfected with a Fyn (16)-eGFP construct (12) and seeded onto 25-mm glass coverslips 24 h after transfection. 12 h later, cells were washed twice with DMEM and were treated overnight with or without 2-bromopalmitate (100 M) or 2-OH-myristate (100 M) as described above. Coverslips were washed with Hanks' buffered saline solution and mounted onto glass microscope slides. Live cell GFP fluorescence was observed with 40ϫ and 63ϫ oil immersion lenses on a Zeiss Axioplan2 microscope and photographed with Kodak TMAX 400.
T Cell Activation and Phosphotyrosine Immunoblots-Jurkat T cells (2 ϫ 10 6 to 1 ϫ 10 7 ) were centrifuged at 1,000 ϫ g for 5 min, rinsed with RPMI, resuspended in RPMI supplemented with 2% dialyzed FBS, 0.5% defatted BSA, and incubated with or without 100 M 2-bromopalmitate at 8 ϫ 10 5 cells/ml for 3 h. The cells were centrifuged, washed with RPMI, and resuspended in RPMI at 1 ϫ 10 7 to 1 ϫ 10 8 cells/ml. The cells were then activated with anti-CD3 OKT3 mAb (0.3 mg/ml) for 3 min at 37°C, quickly spun down, washed once with cold RPMI and once with cold STE, and lysed in RIPA. Samples were solubilized in 1ϫ SDS-PAGE sample buffer containing 5% ␤-mercaptoethanol and subjected to SDS-PAGE, followed by immunoblotting with anti-phosphotyrosine antibody (PY99). For analysis of specific proteins, RIPA lysates were immunoprecipitated with the specific antibodies overnight and immunoblotted for phosphotyrosine. Alternatively, proteins were im-munoprecipitated from the cell lysates with agarose-conjugated antiphosphotyrosine antibody and immunoblotted for the specific proteins. Total protein levels were monitored by subjecting aliquots of the above samples to SDS-PAGE followed by immunoblotting for the specific proteins.
Isolation of DRMs-Isolation of Triton X-100-resistant and -soluble fractions was carried out as described previously (12). Isolation of DRMs by sucrose gradients were carried out as follows (19) : Jurkat cells (5 ϫ 10 7 ) were treated with or without 2-bromopalmitate, activated with OKT3 mAb as described above, and lysed in 1 ml of lysis buffer (25 mM MES, pH 6.5, 150 mM NaCl, 0.5% Triton X-100, 1 mM Na 3 VO 4 ) supplemented with protease inhibitors for 30 min at 0°C. After homogenizing 10 times with a loose fit Dounce homogenizer, lysates were mixed with 1 ml of 85% sucrose in MBS (25 mM MES, pH 6.5, 150 mM NaCl) and overlayered with 6 ml 30% sucrose in MBS and then with 4 ml of 5% sucrose in MBS. Following centrifugation for 16 h at 145,000 ϫ g in an SW40 rotor, 1-ml fractions were collected and analyzed by PAGE and immunoblotting with anti-Fyn, anti-LAT, or anti-Lck antibodies.
For isolation of DRMs in PUFA-treated COS-1 cells, a confluent 100-mm plate of COS-1 cells, untransfected for the analysis of caveolin, or transiently transfected with Fyn cDNA was washed with STE and subjected to the same procedure described above. Fractions were analyzed for the presence of Fyn or caveolin by immunoblotting.
Detergent Extraction of Membranes-COS-1 cells expressing Fyn were left untreated or treated with 2-bromopalmitate or PUFAs and fractionated into P100 and S100 fractions as described above. P100 fractions were resuspended in 10 mM Tris-HCl, pH 7.4, 0.2 mM MgCl 2 , extracted with 0.8 ml of Csk buffer (12), and subjected to ultracentrifugation for 1 h at 200,000 ϫ g at 4°C. Pellets and supernatants were resuspended in RIPA buffer and analyzed by SDS-PAGE and immunoblotting for Fyn.
Calcium Mobilization Assay-Jurkat cells were treated with 2-bromopalmitate as described above. The cells (2 ϫ 10 5 ) were collected by centrifugation and resuspended at 2 ϫ 10 6 cells/ml in RPMI containing in 50 M fluo-3 with or without 100 M 2-bromopalmitate for 30 min at room temperature. Cells loaded with fluo-3 were then collected by centrifugation at 1,000 ϫ g, washed with Hanks' buffered saline solution (5.4 mM KCl, 0.3 mM Na 2 HPO 4 , 0.4 mM KH 2 PO 4 , 4 mM NaHCO 3 , 1.3 mM CaCl 2 , 0.5 mM MgCl 2 , 0.6 mM MgSO 4 , 137 mM NaCl, 5.6 mM glucose, 20 mM Hepes, pH 7.4) and resuspended in the same buffer at a density of 5 ϫ 10 5 cells/ml at 37°C. To initiate calcium flux, the cells were activated with OKT3 antibody as described above and analyzed for free calcium ion by measurement of fluo-3 fluorescence emission by flow cytometry.
For analysis of CD3 positive cells, 1 ϫ 10 6 cells were centrifuged, washed, and resuspended in 100 l of ice-cold phosphate-buffered saline (136 mM NaCl, 2.6 mM KCl, 4.3 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ) containing 1% FBS. OKT3 antibody was added to a final concentration of 0.3 mg/ml. Following 30 min on ice, the cells were washed twice with phosphate-buffered saline/1% FBS and incubated at 0°C for an additional 30 min with an fluorescein isothiocyanate-conjugated goat antimouse secondary antibody (1:20 dilution). The cells were washed twice, resuspended in phosphate-buffered saline/1% FBS, and subjected to fluorescence-activated cell sorter analysis.
Activation of MAPK-Jurkat cells were treated with 2-bromopalmitate and activated as described above. Lysates were analyzed for the presence of active MAPK by immunoblotting with a pERK antibody and for total MAPK by immunoblotting with an anti-MAPK antibody.
RESULTS

Identification of 2-Bromopalmitate as an Inhibitor of Fyn
Fatty Acylation-We screened a number of palmitic acid analogs for their ability to inhibit Fyn palmitoylation. COS-1 cells were transfected with pCMV5 Fyn. Three days after transfection, the cells were labeled with either [ 35 S]methionine, IC13, an iodinated myristate analog, or IC16, an iodinated palmitic acid analog (39) , in the presence or absence of nonradioactive palmitate analogs. Cells were lysed, immunoprecipitated with anti-Fyn antibody, and analyzed by SDS-PAGE and phosphorimaging. 2-Bromopalmitate efficiently inhibited Fyn fatty acylation (Fig. 1A) . When normalized for total protein levels, 70 Ϯ 7% of Fyn myristoylation and over 90 Ϯ 8% of Fyn palmitoylation was inhibited in the presence of 2-bromopalmitate. Treatment of cells with other analogs, including 2-hydroxypalmitate, palmitoleic acid, and 16-hydroxypalmitate had no effect (data not shown).
Effect of 2-Bromopalmitate on Subcellular Localization of Fyn-Newly synthesized Fyn becomes plasma membranebound within 5 min after biosynthesis (12). The rapid membrane targeting is dependent on dual fatty acylation of Fyn with myristate and palmitate. We next examined the effect of 2-bromopalmitate on the ability of newly synthesized Fyn to localize to membranes. Transfected COS-1 cells were incubated for 12-16 h with or without 100 M 2-bromopalmitate. Cells were then metabolically labeled with [
35 S]methionine for 5 min followed by fractionation into cytosolic (S100) or membrane (P100) fractions. As depicted in Fig. 1B , in untreated cells, 85 Ϯ 8% of the labeled Fyn was membrane-bound. In cells treated with 2-bromopalmitate, 49 Ϯ 4% of Fyn remained cytosolic, demonstrating the ability of the reagent to partially block membrane association of newly synthesized Fyn. The effect of 2-bromopalmitate on membrane localization of steady-state Fyn was also examined. Transfected cells were treated with 2-bromopalmitate as described above, then fractionated, and immunoprecipitated with anti-Fyn followed by Western blotting with anti-Fyn antibody. The effect of 2-bromopalmitate on membrane localization of steady-state Fyn was identical to the effect on newly synthesized Fyn, with 50% of the Fyn protein fractionating in the cytosol (data not shown). These results mimic the fractionation pattern of a nonpalmitoylated Fyn mutant (C3,6SFyn) and of a nonmyristoylated Fyn mutant (G2AFyn) and strongly suggest that the redistribution of Fyn observed in 2-bromopalmitate-treated cells is due to inhibition of Fyn fatty acylation (13) .
Previous experiments have shown that following rapid membrane binding of newly synthesized Fyn, there is a slower partitioning of Fyn (10 -20 min) to regions of the plasma membrane that are resistant to Triton X-100 extraction at 4°C (12). We therefore examined the effect of 2-bromopalmitate on the localization of Fyn to Triton X-100-insoluble fractions. Transfected COS-1 cells were left untreated or treated with 2-bromopalmitate as described above. Cells were extracted with buffer containing 1% Triton X-100, and samples were subjected to immunoprecipitation and Western blotting with anti-Fyn antibodies. As depicted in Fig. 1C , in untreated cells the majority of Fyn was associated with detergent-resistant fractions (R), in agreement with previous experiments (12). In comparison, Fyn in 2-bromopalmitate-treated cells was mostly soluble, demonstrating the ability of 2-bromopalmitate to partially block association of Fyn with detergent-resistant membrane subdomains. To verify that lateral targeting of Fyn to DRMs was being affected, isolated membranes were treated with Triton X-100, and DRMs were isolated by ultracentrifugation. We used 0.05% Triton X-100 for the extraction, because DRMs from isolated membranes are more sensitive to detergent extraction compared with whole cells (40) . As depicted in Fig. 1D , nearly 83 Ϯ 6% of the membrane-associated Fyn from control cells was resistant to detergent extraction, with only 17% of the Fyn appearing in the solubilized fraction. In contrast, 44 Ϯ 7% of the Fyn from 2-bromopalmitate-treated cell membranes was solubilized with Triton. These data imply that 2-bromopalmitate affects lateral targeting of Fyn to DRMs.
To investigate the effect of 2-bromopalmitate on the intracellular localization of Fyn more precisely, we examined COS-7 cells expressing a Fyn(16)-eGFP construct by immunofluorescence. This construct contains the first 16 amino acids of Fyn fused in frame to eGFP; the chimera is targeted to the plasma membrane and DRMs (12). Cells were cultured with no treatment, with 2-bromopalmitate, or with 2-hydroxymyristate, a known myristoylation inhibitor (41, 42) as described above and were examined live by fluorescence microscopy. Fig. 2A shows that Fyn(16)-eGFP is primarily distributed in the plasma membrane with very little perinuclear staining (top panels). In contrast, cells treated with 2-bromopalmitate (middle panels) and 2-hydroxymyristate (bottom panels) exhibited a distinct and predominant perinuclear staining, presumably representing cytosolic and intracellular membrane distribution, in addition to plasma membrane staining. Analysis of the subcellular localization of Fyn(16)-eGFP in the presence of 2-bromopalmitate and 2-hydroxymyristate was performed as described above for steady-state Fyn. As depicted in Fig. 2B , in the absence of treatment, 80% of Fyn(16)-eGFP Fyn was membrane-bound, whereas in cells treated with 2-bromopalmitate and 2-hydroxymyristate, 65 and 78% of Fyn(16)-eGFP were cytosolic, respectively. These results strengthen the hypothesis that fatty acylation of Fyn is important for the proper localization of the protein within the cell. (43, 44) . The neuronal protein GAP43 (neuromodulin) is palmitoylated near the N terminus at cysteines 3 and 4 but is not myristoylated (45) . Finally, the oncogenic Ha-Ras protein is palmitoylated just upstream of the C-terminal CAAX box (46) .
Effect of 2-Bromopalmitate on Membrane Localization of Other Palmitoylated Proteins-Palmitoylation
Each of these three sequences was appended onto the Fyn protein. G␣ o (10)-Fyn and GAP43(10)-Fyn are chimeric constructs with the first 10 amino acids of G␣ o or GAP-43, respectively, in place of the first 10 amino acids of wild type Fyn. These constructs have been previously described (12, 13). In addition, the Ha-Ras tail was fused to the C terminus of a nonacylated Fyn mutant (G2A,C3SFyn-Ha-Ras). This construct contains full-length Fyn with mutations in the N-terminal myristoylation and palmitoylation sites but with the C terminus of Ha-Ras available for prenylation and palmitoylation. Finally, an oncogenic G12V full-length Ha-Ras construct was tested. As depicted in Fig. 3 (A and B) , 2-bromopalmitate inhibited membrane binding of the two N-terminal palmitoylated proteins, G␣ o (10)-Fyn and GAP43(10)-Fyn, to the same extent as wild type Fyn. In untreated cells, 90 Ϯ 3% of G␣ o (10)Fyn was membrane-bound, compared with 40 Ϯ 1% in cells treated with 2-bromopalmitate. Likewise, GAP43(10)-Fyn was mostly membrane-bound (68 Ϯ 7%) in untreated cells, compared with 28 Ϯ 10% in 2-bromopalmitate-treated cells. In the same experiment, 2-bromopalmitate induced a 50 Ϯ 3% shift of wild type Fyn from membrane to cytosol (data not shown). Thus, for N-terminal palmitoylated proteins, 2-bromopalmitate induces a 40 -50% shift from membrane to cytosol. In contrast, 2-bromopalmitate had a lesser effect on the membrane localization of the two Ras constructs (Fig. 3, C and D) . , lysed, and subjected to immunoprecipitation with anti-Fyn antibody. Lysates were subjected to SDS-PAGE followed by phosphorimaging. This experiment was performed three times in duplicate with similar results. B, cells were radiolabeled with Tran 35 S-label for 5 min, fractionated into particulate P100 (P) fractions and soluble S100 (S) fractions by centrifugation at 100,000 ϫ g, and subjected to immunoprecipitation, SDS-PAGE, and phosphorimaging. This experiment was performed four times in duplicate with similar results. C, cells were lysed in buffer containing 1% Triton X-100. Detergent-soluble (S) and -resistant (R) fractions were clarified at 100,000 ϫ g and subjected to immunoprecipitation and SDS-PAGE followed by immunoblotting with anti-Fyn antibodies. This experiment was performed twice: once in duplicate and treated with 2-bromopalmitate. The G12V Ha-Ras construct migrates as a doublet on a gel. The slower migrating form represents the nonprocessed cytosolic form of Ha-Ras, and the faster migrating form represents the processed Ras, which is membrane-bound. Thus 2-bromopalmitate induces only a modest 7-20% effect of membrane localization of the Ras constructs and thus appears to posses some specificity toward inhibiting membrane localization of N-terminal palmitoylated proteins, in comparison with a protein palmitoylated near the C terminus. The absolute sequence surrounding the palmitoylated cysteine residue did not seem to be important, because the GAP43(10)-Fyn construct was affected to the same extent as wild type Fyn and G␣ o (10)-Fyn.
2-Bromopalmitate Inhibits Fatty Acylation and Localization of Palmitoylated Proteins to DRMs in T Cells-The Src family kinases Fyn and Lck play critical roles in TCR-mediated signaling. Palmitoylation of Fyn and Lck has been shown to be essential for localization to DRMs in T cells, and localization to
DRMs is required for efficient signaling by the activated TCR (11). We tested the ability of 2-bromopalmitate to inhibit Fyn fatty acylation in Jurkat T cells. Cells were transfected by electroporation with cDNA encoding Fyn. Two days after trans-
FIG. 2. Effect of 2-bromopalmitate on localization of Fyn(16)-eGFP in COS-7 cells.
A, cells transiently expressing Fyn(16)-eGFP were preincubated overnight in the absence (top panels) or presence of 100 M 2-bromopalmitate (middle panels) or 100 M 2-hydroxymyristate (bottom panels) and examined live by fluorescence microscopy. This experiment was performed four times with multiple cells examined; representative duplicate images are depicted. B, duplicates of the above samples were subjected to subcellular fractionation into P100 and S100 fractions and subjected to immunoblotting with anti-GFP antibody. 2BP, 2-bromopalmitate; 2OH myr, 2-hydroxymyristate. fection, cells were labeled with IC13 or IC16 as described above for COS cells. Total protein levels were monitored by immunoprecipitation followed by immunoblotting with anti-Fyn antibody. As depicted in Fig. 4A , myristoylation and palmitoylation were inhibited by 75 and 90%, respectively, in 2-bromopalmitate-treated cells, relative to untreated controls, demonstrating the ability of the reagent to inhibit Fyn fatty acylation in Jurkat T cells.
We next tested the ability of 2-bromopalmitate to inhibit localization of palmitoylated proteins to DRMs in activated Jurkat cells. Cells were either left untreated or treated with 100 M 2-bromopalmitate for 3 h, washed and resuspended in serum-free medium, and the TCR was activated with OKT3 mAb. Activated cells were extracted with Triton X-100 containing buffer. Lysates were layered on the bottom of a sucrose gradient as described under "Experimental Procedures" and subjected to overnight ultracentrifugation. Rafts, which contain DRMs, were collected at the 35%/5% sucrose interface (Fig.  4B, fractions 8 -11 ), whereas fractions 1-4 represented the Triton soluble fractions (Fig. 4B) . Each fraction was analyzed by immunoblotting with specific antibodies. 59% of Lck was found in the rafts in control cells, compared with 19% in cells treated with 2-bromopalmitate (top two panels). Likewise, the amount of Fyn found in the rafts was 88% in control cells but only 59% in treated cells (middle two panels). We also examined the effect of 2-bromopalmitate on localization of LAT, another palmitoylated protein in T cells that has been shown to be localized to plasma membrane rafts (10, 20) . The majority of LAT (71%) was found in the DRMs in control cells, whereas in cells treated with 2-bromopalmitate only 41% of the protein remained associated with this fraction (bottom two panels). These data indicate that in Jurkat T cells, 2-bromopalmitate is able to partially block association of endogenous Fyn, Lck, and LAT with rafts.
Effect of 2-Bromopalmitate on Tyrosine Phosphorylation in T Cells-One of the earliest signaling events after TCR activation is the tyrosine phosphorylation of multiple intracellular proteins. The initial phosphorylation events are mediated by activation of Src family kinases. We tested whether 2-bromopalmitate can interfere with signaling through the TCR by analyzing the ability of the compound to block tyrosine phosphorylation in activated T cells. Jurkat cells were incubated with 2-bromopalmitate and activated with OKT3 anti-CD3 antibody. Cell lysates were analyzed by immunoblotting with anti-phosphotyrosine antibodies. In control cells, stimulation with OKT3 antibodies induced tyrosine phosphorylation of multiple proteins (Fig. 5A) . In cells treated with 2-bromopalmitate, the phosphorylation of several proteins was significantly inhibited. The most dramatic effect was on a 36-kDa protein, which represents LAT (see below).
To identify the individual proteins whose tyrosine phosphorylation is affected by 2-bromopalmitate, lysates were immunoprecipitated with a panel of specific antibodies and immunoblotted for phosphotyrosine. Alternatively, lysates were immunoprecipitated with an antiphosphotyrosine antibody and blotted with antibodies to specific proteins. Fig. 5B shows 
Lysates were immunoprecipitated with anti-Fyn antibody (IP).
Bottom panel, to monitor total protein levels, aliquots from each sample were subjected to immunobloting with anti-Fyn antibody. This experiment was performed twice in duplicate with similar results. B, localization to DRMs. Cells were cultured with 2-bromopalmitate as in A, lysed with buffer containing 0.5% Triton X-100, and layered on the bottom of a sucrose gradient as detailed under "Experimental Procedures." After overnight centrifugation, 1-ml fractions were collected, and the DRM localization of endogenous palmitoylated proteins was analyzed by SDS-PAGE and immunoblotting with anti-Lck (top two panels), antiFyn (middle two panels), or anti-LAT (bottom two panels) antibodies. WB, Western blot. that in 2-bromopalmitate-treated cells, CD3-mediated tyrosine phosphorylation of LAT was inhibited almost completely (94 Ϯ 5%). PLC-␥1 phosphorylation was inhibited by 74 Ϯ 11%, Vav phosphorylation was inhibited by 40 Ϯ 10%, ZAP-70 phosphorylation was inhibited by 50 Ϯ 6%, and PI3K phosphorylation was inhibited by 50 Ϯ 10%. Low to moderate increases in tyrosine phosphorylation were observed in the presence of 2-bromopalmitate alone for some of the proteins. The reason for this basal activation is unknown. To verify that the observed inhibition of TCR-mediated tyrosine phosphorylation was not a result of toxicity effects of 2-bromopalmitate, aliquots of each sample were analyzed by immunoblotting with antibodies to the indicated signaling proteins or with anti-actin antibodies. The levels of LAT, PLC-␥1, Vav, ZAP70, PI3K (Fig. 5B) , and actin (not shown) were not affected by 2-bromopalmitate. Thus 2-bromopalmitate is able to inhibit signaling through the TCR, as assayed by its ability to inhibit tyrosine phosphorylation of key substrate proteins.
2-Bromopalmitate Inhibits Calcium Mobilization in T Cells-TCR activation results in increased Ca
2ϩ mobilization in stimulated T cells. The increase in Ca 2ϩ flux is mediated by tyrosine phosphorylation and activation of PLC-␥1. PLC-␥1 hydrolyzes phosphatidylinositol 4,5-bisphosphate to inositol 1,4,5-triphosphate, which promotes calcium release from the endoplasmic reticulum (47) . We next assayed the ability of 2-bromopalmitate to interfere with calcium release by flow cytometry. Jurkat cells were incubated with or without 2-bromopalmitate, washed, and stained with the fluorescent dye fluo-3 (50 M). Cells were activated with OKT3 antibody and analyzed by flow cytometry. Fig. 5 shows that in response to TCR activation, T cells treated with 2-bromopalmitate were severely impaired in their ability to release calcium compared with control cells (Fig. 6, A and B) . Quantitation of the data revealed that calcium flux shut down almost completely in the presence of 2-bromopalmitate. No effect of 2-bromopalmitate on cells incubated in the absence of OKT3 was noted. To ensure that the observed inhibition of calcium flux was not due to a decreased expression of CD3 in 2-bromopalmitate-treated cells, Jurkat cells were incubated with OKT3 antibody at 0°C, followed by incubation with a fluorescein isothiocyanate-conjugated goat anti-mouse secondary antibody. The percentage of CD3-positive cells was analyzed by fluorescence-activated cell sorter analysis. Over 95% of the cells were found to be positive for CD3 in control and 2-bromopalmitate-treated cells (data not shown).
2-Bromopalmitate Inhibits MAPK Activation-One of the proximal events following TCR engagement is activation of the MAPK pathway. We tested the ability of 2-bromopalmitate to inhibit activation of MAPK in Jurkat cells. Cells were cultured with or without 2-bromopalmitate and activated as described above. Cell lysates were subjected to SDS-PAGE and immunoblotted with anti-active MAPK kinase (pERK1). As depicted in Fig. 7, 2 -bromopalmitate inhibited the activation of MAPK kinase by 70 Ϯ 6%. The levels of total MAPK kinase remained unchanged (Fig. 7) .
PUFAs Inhibit Fyn Palmitoylation and Localization to DRMs in COS-1 Cells-The data reported above identify 2-bromopalmitate as an inhibitor of protein fatty acylation and TCR-mediated signaling. We next examined whether other fatty acids, particularly long chain unsaturated compounds, might also interfere with protein fatty acylation. It has recently been reported that PUFAs inhibit T cell signal transduction by displacing Src kinases Fyn and Lck from the DRMs (37). This inhibition was speculated to be due to PUFA-induced disruption of DRM structure and composition. Based on our results with 2-bromopalmitate, we suspected that PUFA-induced displacement of Fyn/Lck from the DRMs was actually due to alterations of S-acylation. To test this hypothesis, Fyn transfected COS-1 cells were incubated overnight with or without 50 M arachidonic acid (20:4) or eicosapentaenoic acid (20:5) and then labeled with IC13 or IC16. Total protein levels were monitored by immunoblotting aliquots of each sample with antiFyn antibody (Fig. 8A, lower panel) . As depicted in Fig. 8A , Fyn myristoylation was not affected by PUFA treatment to a significant effect (Fig. 8B) . On the other hand, Fyn palmitoylation was affected quite dramatically. Arachidonic acid inhibited incorporation of IC16 into Fyn by 65% and eicosapentaenoic acid by 73% (Fig. 8C) . These reductions in palmitate incorporation correlate well with the previously reported observation that 20:5 is slightly more potent than 20:4 in inhibiting T cell signaling and in displacing Fyn and Lck from DRMs (37) . In the same report, the PUFA docosahexaenoic acid (22:6) was less active than 20:4 and 20:5 and only moderately inhibited Fyn/Lck displacement from DRMs and TCR signaling. In agreement with these findings, we found that 22:6 was 10 -20% less potent than 20:4 and 20:5 at inhibiting Fyn palmitoylation (data not shown).
We next asked whether 20:4 and 20:5 can inhibit localization
FIG. 5. Tyrosine phosphorylation of signaling proteins in Jurkat T cells.
A, Jurkat cells were treated without or with 2-bromopalmitate for 3 h and then were either left unactivated (Ϫ) or activated (ϩ) with OKT3 mAb (0.3 mg/ml) for 3 min and lysed. Lysates were subjected to SDS-PAGE followed by immunoblotting with anti-phosphotyrosine antibody (PY99). Similar patterns were obtained on multiple (Ͼ5) repetitions of this experiment. B, cells were treated and lysed as described for A. Left panels, lysates were immunoprecipitated with agarose-conjugated phophotyrosine antibody (PY99) and immunblotted for specific proteins. Alternatively, lysates were immunoprecipitated for specific proteins and immunoblotted with antiphosphotyrosine antibody. Right panels, an aliquot of the total lysate was analyzed directly by Western blotting for total levels of the indicated proteins. The data are representative of duplicate samples, each performed one to three times.
of Fyn to DRMs in COS-1 cells. Cells were treated with or without PUFAs as described above and layered on the bottom of a sucrose gradient as described under "Experimental Procedures." Fractions were collected and analyzed by immunoblotting with anti-Fyn antibody. As depicted in Fig. 8D , in untreated cells, 30 Ϯ 6% of Fyn localized to DRMs, in agreement with previous findings (48) . Treatment with PUFAs markedly reduced the ability of Fyn to localize to DRMs, with only 16 Ϯ 6% of Fyn found in DRMs in 20:4 treated cells and 5 Ϯ 3% in 20:5 treated cells. A similar result was obtained when membranes were first isolated from PUFA-treated cells and then extracted with detergent. Membranes prepared from PUFAtreated cells contained decreased amounts of Fyn in the DRMs compared with control cell membranes (data not shown). These findings clearly demonstrate that PUFAs alter the lateral distribution of Fyn in the plasma membrane.
To determine whether PUFA treatment altered DRM structure, we examined the distribution of caveolin in control and PUFA-treated cells. Like Fyn, caveolin is localized to the inner leaflet of the DRM. Although caveolin is palmitoylated, palmitoylation is not required for localization of caveolin to DRMs or caveolae (49) . As depicted in Fig. 8E , PUFA treatment of COS-1 cells did not reduce the localization of caveolin to DRMs; the majority of the caveolin fractionated with the DRMs in both control and PUFA-treated cells. We conclude that the displacement of Fyn from DRMs is likely due to a PUFA-induced reduction in Fyn palmitoylation rather than an overall effect of PUFAs on DRM structure. DISCUSSION 
2-Bromopalmitate Inhibits Fyn Fatty Acylation in COS-1
Cells-The ability of Src family members Fyn and Lck to participate in signaling through the T cell receptor is critically dependent on their fatty acylation with myristate and palmitate. In this study, we have identified 2-bromopalmitate as an inhibitor of Fyn fatty acylation and membrane targeting. This was accomplished by screening palmitate analogs for their ability to inhibit incorporation of myristate and palmitate into Fyn in transiently transfected COS-1 cells. We show that this inhibition results in decreased membrane binding and localization to DRMs. Moreover, 2-bromopalmitate inhibits fatty acylation and localization of Fyn, Lck, and LAT to DRMs in Jurkat T cells. Consequently, this results in impaired signaling through the T cell receptor, as shown by a reduction in tyrosine phosphorylation, calcium flux, and activation of the MAPK pathway. Furthermore, we show that PUFAs arachidonic acid (20:4) and eicosapentaenoic acid (20:5) are specific inhibitors of Fyn palmitoylation and localization to DRMs in COS-1 cells. This may account for the ability of these compounds to inhibit T cell signaling as reported previously (37) and may be a mechanism by which these agents exert their immunosuppressive and anti-inflammatory effects.
We have previously shown that protein palmitoylation oc- curs within an N-terminal Myr-Gly-Cys motif and that this event is dependent on myristoylation (12, 13). The ability of 2-bromopalmitate to partially inhibit myristoylation likely accounts for some of the reduction in palmitoylation. However, the extent of inhibition by 2-bromopalmitate on Fyn palmitoylation is always greater than that on myristoylation, implying that 2-bromopalmitate has additional, direct effects on palmitoylation (Figs. 1A and 4A) . A direct effect on palmitoylation is also supported by the observation that 2-bromopalmitate inhibits membrane localization of a GAP43(10)-Fyn construct, which is palmitoylated but not myristoylated (Fig. 3B) . Furthermore, 2-hydroxymyristate, a known inhibitor of myristoylation (41, 42) , inhibits membrane localization of Fyn and Fyn (16)-eGFP to a greater extent than 2-bromopalmitate (Fig. 2B) . This implies that 2-bromopalmitate-treated cells contain a population of myristoylated, nonpalmitoylated Fyn that has a greater affinity for membranes than nonacylated Fyn. Finally, the membrane localization of Fyn in the presence of 2-bromopalmitate resembles that of the myristoylated, nonpalmitoylated C3,6S Fyn mutant previously studied in our laboratory (13) . We conclude that 2-bromopalmitate is an inhibitor of protein fatty acylation with some specificity for palmitoylation.
Two possible mechanisms may account for the inhibitory effect of 2-bromopalmitate on palmitoylation. One possibility is that 2-bromopalmitate binds to PAT, but because of the steric bulk of the bromine, it cannot be transferred to the acceptor protein. Alternatively, 2-bromopalmitate may serve as a substrate for PAT. In this case, Fyn would be S-acylated with 2-bromopalmitate, but hydrophilic and steric effects of the bromine atom would reduce the affinity of the protein for membranes. In the absence of a radiolabeled form of 2-bromopalmitate, it is not possible at this point to distinguish between these two possibilities. Fig. 4 indicate that 2-bromopalmitate inhibits Fyn fatty acylation and localization to DRMs in Jurkat T cells. As a result, there is a marked reduction in tyrosine phosphorylation of key signaling molecules in CD3-stimulated cells (Fig. 5) , suggesting that signaling via the TCR is impaired. Interestingly, some proteins show an increase in the level of phosphorylation in 2-bromopalmitate-treated cells as compared with control cells, even in the absence of CD3 stimulation. Although the basis for this basal activation is unknown, it does not seem to be related to TCR activation, because there is no effect on Ca ϩ2 flux or activation of MAPK pathway in unstimulated 2-bromopalmitate-treated cells. We cannot exclude the possibility that 2-bromopalmitate has additional effects on cellular kinases or phosphatases. If the basal activation is taken into account, then the reduction of tyrosine phosphorylation on the signaling molecules examined ranges from 70 to 100% (Fig. 5B) .
2-Bromopalmitate Inhibits Fyn Fatty Acylation and Signaling in Jurkat T Cells-The experiments depicted in
PUFAs Inhibit Fyn Palmitoylation and Localization to DRMs in COS-1 Cells-PUFAs modulate immune responses by affecting T cell function (50) . Therefore, these agents (particularly the n-3 series) have found clinical applications in the treatment of various inflammatory diseases such as rheumatoid arthritis and Crohn's disease relapses (33, 35, 36) and as immunosuppressive agents (32) . Despite the broad clinical use of PUFAs, the mechanism of PUFA-induced T cell inhibition had not been elucidated. Recently, it was reported that the PUFA-induced inhibition of T cell activation is due to displacement of Src family kinases from the cytoplasmic layer of the DRMs (37) . This displacement was hypothesized to be mediated by modification of the DRM structure and composition. Here we show that exclusion of the Src family kinase Fyn from DRMs in PUFA-treated cells is likely due to inhibition of palmitoylation.
We cannot exclude the possibility that the PUFAs are induc- ing changes in the lipid architecture of the membrane and that this may account at least in part for the displacement of Src kinases from the DRMs. However, we show (Fig. 8E ) that caveolin, another protein localized to the inner leaflet of the DRM, is not displaced from this fraction in response to PUFA treatment. This strongly supports our hypothesis that PUFA-induced dislocation of Fyn from DRM is primarily due to inhibition of fatty acylation rather than a general effect on DRM structure.
In contrast to the saturated inhibitor 2-bromopalmitate, polyunsaturated arachidonic acid (20:4) and eicosapentaenoic acid (20:5) have almost no effect on Fyn myristoylation and are rather specific for palmitoylation. Several lines of evidence suggest that the mechanism of inhibition of palmitoylation involves the use of PUFAs as alternative substrates for Sacylation to Fyn. First, studies of partially purified preparations of PAT reveal that longer chain fatty acyl CoAs, including stearate (18:0) and arachidonate (20:4) , can compete with palmitate for incorporation into Fyn and G␣ o (26, 27) . Second, G␣ subunits, P-selectin, asialoglycoprotein receptor, and several platelet proteins have been shown to be S-acylated with stearate, arachidonate, and eicosapentaenoate, in addition to palmitate (51, 52) . These results indicate that the fatty acid specificity of PAT and S-acylation is loose in vivo and in vitro. Third, immunoprecipitation of Fyn from cells radiolabeled with [ 3 H]arachidonate revealed a faint band after a 6-week exposure of the fluorogram that was comparable in intensity with that obtained from a [
3 H]palmitate-labeled sample. Finally, Fyn localization to the plasma membrane fraction was not affected by PUFAs (data not shown), even though incorporation of [ 125 I]IC16 was markedly reduced. Because myristoylation alone is not sufficient for stable membrane binding, it is likely that Fyn becomes dually fatty acylated by N-myristoylation and S-acylation with a PUFA. The presence of myristate ϩ PUFA at the N terminus of Fyn would provide strong affinity for binding to a membrane bilayer. However, the presence of a polyunsaturated, bulky acyl chain in the PUFA would preclude specific localization to DRMs, which, because of their liquid ordered domain structure, provide a local environment conducive to insertion of saturated but not unsaturated fatty acid chains (18) .
In conclusion, we have found that specific fatty acids and fatty acid analogs function as inhibitors of protein fatty acylation and TCR-mediated signaling. The advantage of using inhibitors that interfere with subcellular localization of a key protein is that it allows one to study signaling by endogenous cellular proteins and eliminates the need to overexpress mutant proteins. Thus, 2-bromopalmitate can be used as a powerful tool to study the role of Src kinases in the endogenous T cell signaling system and may provide insight into the role of signaling in the onset of disease. We have also shown that PUFA-induced inhibition of T cell activation is likely due to the inhibition of Src kinase palmitoylation. Although these agents are currently used in the clinic, their mechanism of action is still largely unknown. We propose a novel mechanism, inhibition of protein palmitoylation, which may account for the abilities of PUFAs to treat or prevent a broad range of immunebased diseases.
